Starpharma Holdings Ltd has released a press release.
VIRALEZE well tolerated in multiple dose clinical study
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- VIRALEZE SPL7013 virucidal against SARS-CoV-2 Delta variant
- VIRALEZE UK Update
- VIRALEZE SPL7013 virucidal against multiple COVID variants
- VIRALEZE antiviral nasal spray registered for sale in India
- VIRALEZE SPL7013 highly active in UK variant of coronavirus
Later from Starpharma
- VIRALEZE Protects Against SARS-CoV-2 in Challenge Model
- VIRALEZE launch in ADMENTA Italia Group pharmacies in Italy
- VIRALEZE distribution and supply to Vietnam
- Positive DEP phase 2 interim results in prostate cancer
- AGM Chairman address and CEO presentation
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma